Your browser doesn't support javascript.
loading
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.
Qin, Shuqui; Li, Jin; Zhou, Aiping; Zhang, Yanqiao; Yuan, Xianglin; Zhu, Liangjun; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Wang, Weibo; Liang, Jun; Zhang, Xianwen; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhenyan; Yue, Lu; Fang, Yong; Xiong, Jianping; Yang, Jianwei; Wan, Yiye; Yin, Xianli; Wang, Wenling; Xu, Nong; Wang, Xiaohong; Xiao, Zemin; Su, Huafang; Wang, Ying; Gu, Kangsheng; Tu, Shuiping; Wang, Zishu; Liu, Bo; Hu, Xiaohua; Liu, Weixian; Li, Xiaofeng.
Afiliación
  • Qin S; Department of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China.
  • Li J; Department of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China.
  • Zhou A; Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.
  • Zhang Y; Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
  • Yuan X; Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
  • Zhu L; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.
  • Qin B; Department of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
  • Zeng S; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
  • Shen L; Department of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
  • Yuan Y; Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
  • Wang W; Department of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China.
  • Liang J; Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China.
  • Zhang X; Department of Medical Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, P. R. China.
  • Ye F; Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China.
  • Chen P; Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China.
  • Wang H; Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
  • Yu Z; Department of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China.
  • Yue L; Department of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China.
  • Fang Y; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
  • Xiong J; Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.
  • Yang J; Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.
  • Wan Y; Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.
  • Yin X; Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
  • Wang W; Department of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
  • Wang X; Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
  • Xiao Z; Department of Oncology, The First People's Hospital of Changde City, Changde, Hunan, P. R. China.
  • Su H; Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.
  • Wang Y; Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
  • Gu K; Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
  • Tu S; Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
  • Wang Z; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China.
  • Liu B; Department of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China.
  • Hu X; Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
  • Liu W; Department of Medical Oncology, Binzhou People's Hospital, Binzhou, Shandong, P. R. China.
  • Li X; Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China.
Cancer Commun (Lond) ; 44(8): 910-914, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38976318
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Sistema de Registros / Irinotecán Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Commun (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Sistema de Registros / Irinotecán Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Commun (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos